Tear protein changes before and after low-level light therapy for dry eye and meibomian gland dysfunction
Official title: Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
Run by Singapore National Eye Centre · NCT07329712 · Data updated 2026-11-12
This research will test whether low-level light therapy changes proteins in tears and helps people with dry eye and meibomian gland problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Singapore National Eye Centre Government |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | November 5, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | January 9, 2026 |
| Trial ID | NCT07329712 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥21 years) with dry eye and meibomian gland dysfunction who are eligible for and have consented to low-level light therapy and do not have an acute eye problem.
✕Probably not a fit
Patients who are pregnant, have implanted electronic or metal prosthetics, epilepsy, uncontrolled cardiovascular or metabolic conditions, active infections or wounds on the eyelids, bleeding/coagulation disorders, or who present with an acute painful or vision‑threatening eye problem are not suitable and likely will not benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect tear samples from adults with dry eye and meibomian gland dysfunction who are eligible for low-level light therapy, both before and after treatment. Researchers will use proteomics and cytokine analysis to look for molecular changes and markers linked to good treatment response. Participants must be at least 21 years old, able to consent, and not presenting with an acute eye problem. The work is based at the Singapore Eye Research Institute and involves in-person tear collection and laboratory analysis.
Why it matters
Potential benefit: If successful, the study could identify tear protein markers that predict who is likely to benefit from low-level light therapy, enabling more personalized treatment.
How similar studies have gone: Some light-based treatments for meibomian gland dysfunction have shown symptom improvement in prior studies, but using tear proteomics to predict response is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Must be eligible for, and have consented for low level light therapy 2. Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye 3. Ability to give informed consent. 4. Age more or equals to 21 years old. Exclusion Criteria: 1. Patients who are unable to or decline to give consent. 2. Age less than 21 years old. 3. Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye. 4. Patients not suitable for low level lighttherapy: * Pregnant * Fitted with pacemakers, metal, electrical, acoustic prosthetics * Epilepsy, cardiac rhythm or frequency disorders * Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months * Uncontrolled hypertension or severe diabetes * Open wounds on eyelid or skin * Evolving cancer or hepatitis * Blood anticoagulant or coagulation defect
Where it's running
-
Singapore Eye Research Insititute
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Louis Tong, PhD — Singapore Eye Research Institute
- Study coordinator: Louis Tong Tong, PhD
- Email: louis.tong.h.t@singhealth.com.sg
- Phone: 65767200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-level red light therapy and eyelid temperature across different skin tones
This will see if low-level red light therapy changes eyelid temperature in adults with dry eye and meibomian gland dysfunction who have lighter versus darker skin.
-
TearCare treatment for stable corneal measurements before cataract surgery
This study tests whether TearCare therapy followed by gland expression helps stabilize the tear film so pre-surgery measurements for cataract planning are more reliable for people with dry eye and meibomian gland dysfunction.
-
Lacrifill to Help Prevent Post-Curgery Dry Eye After Cataract Surgery
This study tests Lacrifill to see if it helps prevent dry eye symptoms after unilateral cataract surgery.
-
Tear-Fluid Stability Testing with iTrace, BOSA, OPD-Scan III, and IDRA for Dry Eye
A Phase 4 study tests whether four eye devices can detect tear film stability in adults with normal tear film.
-
OT202 1% eye drops for moderate to severe dry eye
This phase 3 study tests whether 1% OT202 eye drops help people with moderate to severe dry eye better than a placebo.
-
Tyrvaya Nasal Spray for Comfort in Contact Lens Wearers
This study tests whether using Tyrvaya twice daily can improve comfort for adults who wear soft contact lenses and have dry eye symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.